Q-omics provides the consensus-scored PRR18 profile across patient tissues and cancer cell-line models. PRR18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRR18 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PRR18 RNA expression shows 12,263 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, THCA, and TGCT as cancer lineages where PRR18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR18 survival associations across molecular data types. PRR18 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR18 RNA expression–survival associations across cancer types. High PRR18 expression shows unfavorable associations in MESO and ESCA, but favorable associations in PAAD, KIRP, SCLC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for PRR18 RNA expression.
This table summarizes PRR18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRR18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR18 shows lower tumor expression in THCA, KICH, KIRC, LIHC, BRCA and CHOL. The THCA box plot shows higher PRR18 RNA expression in normal versus tumor tissue (log2 FC = −0.515, t-test p < 0.001).
This table shows molecular features associated with PRR18 in patient tissues and cancer cell lines. In patient samples, PRR18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
